Recent Finacing
Recent Raise
ArriVent Biopharma in-licenses ex-China rights to therapeutics from China and emerging biotech hubs, developing oncology candidates—anchored by brain-penetrant EGFR inhibitor furmonertinib—for Western clinical programs.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at ArriVent Biopharma.
